Found: 34
Select item for more details and to access through your institution.
Tyrosine kinase inhibitors and anti-angiogenic therapies in kidney cancer.
- Published in:
- 2007
- By:
- Publication type:
- journal article
Localised non‐metastatic sarcomatoid renal cell carcinoma: a 31‐year externally verified study.
- Published in:
- BJU International, 2024, v. 133, n. 2, p. 169, doi. 10.1111/bju.16125
- By:
- Publication type:
- Article
Adjuvant therapy in patients with sarcomatoid renal cell carcinoma: post hoc analysis from Eastern Cooperative Oncology Group‐American College of Radiology Imaging Network (ECOG‐ACRIN) E2805.
- Published in:
- BJU International, 2022, v. 129, n. 6, p. 718, doi. 10.1111/bju.15587
- By:
- Publication type:
- Article
Adjuvant therapy for renal cell carcinoma.
- Published in:
- Current Oncology Reports, 2008, v. 10, n. 3, p. 245, doi. 10.1007/s11912-008-0037-4
- By:
- Publication type:
- Article
Longitudinal and dynamic measurement invariance of the FACIT-Fatigue scale: an application of the measurement model of derivatives to ECOG-ACRIN study E2805.
- Published in:
- 2018
- By:
- Publication type:
- journal article
Patient-Reported Outcomes in KEYNOTE-564: Adjuvant Pembrolizumab Versus Placebo for Renal Cell Carcinoma.
- Published in:
- Oncologist, 2024, v. 29, n. 2, p. 142, doi. 10.1093/oncolo/oyad231
- By:
- Publication type:
- Article
Phase 1b/2 trial of Ipilimumab, Nivolumab, and Ciforadenant (INC) (adenosine A2a receptor antagonist) in first-line advanced renal cell carcinoma.
- Published in:
- Oncologist, 2023, v. 28, p. S13, doi. 10.1093/oncolo/oyad216.022
- By:
- Publication type:
- Article
ADXS31142 Immunotherapy ± Pembrolizumab Treatment for Metastatic Castration-Resistant Prostate Cancer: Open-Label Phase I/II KEYNOTE-046 Study.
- Published in:
- Oncologist, 2022, v. 27, n. 6, p. 453, doi. 10.1093/oncolo/oyac048
- By:
- Publication type:
- Article
Adjuvant Therapy for Renal Cell Carcinoma: Past, Present, and Future.
- Published in:
- Oncologist, 2014, v. 19, n. 8, p. 851, doi. 10.1634/theoncologist.2014-0105
- By:
- Publication type:
- Article
A Phase I Study of Temsirolimus and Bryostatin-1 in Patients With Metastatic Renal Cell Carcinoma and Soft Tissue Sarcoma.
- Published in:
- Oncologist, 2014, v. 19, n. 4, p. 354, doi. 10.1634/theoncologist.2014-0020
- By:
- Publication type:
- Article
Survival among patients with advanced renal cell carcinoma in the pretargeted versus targeted therapy eras.
- Published in:
- Cancer Medicine, 2016, v. 5, n. 2, p. 169, doi. 10.1002/cam4.574
- By:
- Publication type:
- Article
A Phase II Trial of the Epothilone B Analog Ixabepilone (BMS-247550) in Patients with Metastatic Melanoma.
- Published in:
- PLoS ONE, 2010, v. 5, n. 1, p. 1, doi. 10.1371/journal.pone.0008714
- By:
- Publication type:
- Article
Association between age and sex and mortality after adjuvant therapy for renal cancer.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Axitinib in the treatment of renal cell carcinoma: patient selection and perspectives.
- Published in:
- International Journal of Nephrology & Renovascular Disease, 2016, v. 9, p. 65, doi. 10.2147/IJNRD.S83874
- By:
- Publication type:
- Article
Paired Specimens.
- Published in:
- 2010
- By:
- Publication type:
- Editorial
Mechanisms of Apoptosis Resistance and Treatment Strategies to Overcome Them in Hormone-Refractory Prostate Cancer.
- Published in:
- Cancer (0008543X), 2008, v. 112, n. 8, p. 1660, doi. 10.1002/cncr.23318
- By:
- Publication type:
- Article
Phase 2 trial of epothilone B analog BMS-247550 (ixabepilone) in advanced carcinoma of the urothelium (E3800): a trial of the Eastern Cooperative Oncology Group.
- Published in:
- 2007
- By:
- Publication type:
- journal article
Radiation and immunotherapy: a synergistic combination.
- Published in:
- Journal of Clinical Investigation, 2013, v. 123, n. 7, p. 2756, doi. 10.1172/JCI69219
- By:
- Publication type:
- Article
Real‐world study on the characteristics, post‐nephrectomy journey, and outcomes of patients with early‐stage renal cell carcinoma based on risk groups.
- Published in:
- Cancer Medicine, 2024, v. 13, n. 11, p. 1, doi. 10.1002/cam4.7247
- By:
- Publication type:
- Article
Adherence to oral therapies among patients with renal cell carcinoma: Post hoc analysis of the ECOG‐ACRIN E2805 trial.
- Published in:
- Cancer Medicine, 2021, v. 10, n. 17, p. 5917, doi. 10.1002/cam4.4140
- By:
- Publication type:
- Article
A phase II trial of doxorubicin and gemcitabine in renal cell carcinoma with sarcomatoid features: ECOG 8802.
- Published in:
- Medical Oncology, 2012, v. 29, n. 2, p. 761, doi. 10.1007/s12032-011-9829-8
- By:
- Publication type:
- Article
Multipeptide vaccines for melanoma in the adjuvant setting: long-term survival outcomes and post-hoc analysis of a randomized phase II trial.
- Published in:
- Nature Communications, 2024, v. 15, n. 1, p. 1, doi. 10.1038/s41467-024-46877-6
- By:
- Publication type:
- Article
BLIMP1 and NR4A3 transcription factors reciprocally regulate antitumor CAR T cell stemness and exhaustion.
- Published in:
- Science Translational Medicine, 2022, v. 14, n. 670, p. 1, doi. 10.1126/scitranslmed.abn7336
- By:
- Publication type:
- Article
Adjuvant therapy for high-risk renal cell carcinoma patients.
- Published in:
- Current Urology Reports, 2007, v. 8, n. 1, p. 19, doi. 10.1007/s11934-007-0017-5
- By:
- Publication type:
- Article
Fatigue among patients with renal cell carcinoma receiving adjuvant sunitinib or sorafenib: patient-reported outcomes of ECOG-ACRIN E2805 trial.
- Published in:
- 2018
- By:
- Publication type:
- journal article
Use of Bone Resorption Inhibitors in Metastatic Castration-Resistant Prostate Cancer—20 Years Later, and the Answer Is Still Yes.
- Published in:
- 2021
- By:
- Publication type:
- Opinion
Safety of enzalutamide in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel: Expanded access in North America.
- Published in:
- Prostate, 2015, v. 75, n. 8, p. 836, doi. 10.1002/pros.22965
- By:
- Publication type:
- Article
No Role for Adjuvant Sorafenib or Sunitinib in Locally Advanced Kidney Cancer.
- Published in:
- Personalized Medicine in Oncology, 2015, v. 4, n. 2, p. 118
- By:
- Publication type:
- Article
Disease‐free survival as a predictor of overall survival in localized renal cell carcinoma following initial nephrectomy: A retrospective analysis of Surveillance, Epidemiology and End Results‐Medicare datac.
- Published in:
- International Journal of Urology, 2023, v. 30, n. 3, p. 272, doi. 10.1111/iju.15104
- By:
- Publication type:
- Article
Correction to: Phase I Study of Glesatinib (MGCD265) in Combination with Erlotinib or Docetaxel in Patients with Advanced Solid Tumors.
- Published in:
- 2022
- By:
- Publication type:
- Correction Notice
Phase I Study of Glesatinib (MGCD265) in Combination with Erlotinib or Docetaxel in Patients with Advanced Solid Tumors.
- Published in:
- Targeted Oncology, 2022, v. 17, n. 2, p. 125, doi. 10.1007/s11523-022-00875-0
- By:
- Publication type:
- Article
Vinblastine and estramustine phosphate in metastatic renal cell carcinoma.
- Published in:
- Cancer (0008543X), 2003, v. 98, n. 9, p. 1837
- By:
- Publication type:
- Article
A phase I trial of pembrolizumab with hypofractionated radiotherapy in patients with metastatic solid tumours.
- Published in:
- 2018
- By:
- Publication type:
- journal article
Incidence of Bladder Cancer in Patients With Type 2 Diabetes Treated With Metformin or Sulfonylureas.
- Published in:
- Diabetes Care, 2014, v. 37, n. 7, p. 1910, doi. 10.2337/dc13-1489
- By:
- Publication type:
- Article